Melanoma/Skin Cancer News

Neoadjuvant pembrolizumab extended event-free survival compared with adjuvant-only administration of the anti-PD-1 therapy among patients with resectable melanoma, according to phase 2 study results presented at ESMO Congress.

A single infusion of tumor-infiltrating lymphocytes more than doubled PFS, OS and complete response rates compared with ipilimumab among patients with advanced, unresectable melanoma, study results presented at ESMO Congress showed.

A novel multicancer early detection blood test identified a common signal for more than 50 cancer types and predicted where the signal originated in the body among individuals with undiagnosed cancer.

Neoadjuvant cemiplimab induced a pathologic complete response among a majority of patients with resectable cutaneous squamous cell carcinoma, according to results of a nonrandomized phase 2 study presented at ESMO Congress.

An off-the-shelf T-cell receptor therapy has shown promising early results in multiple solid tumor types, according to initial data from a phase 1 dose-escalation trial presented at ESMO Congress.

FDA issued a safety alert Thursday regarding reports of squamous cell carcinoma and various lymphomas in the scar tissue surrounding breast implants.

Immune checkpoint inhibitor therapy appeared associated with an increased risk for major adverse cardiovascular events among patients with cancer and a prior history of cardiovascular disease, according to results of a retrospective study.

Although they exhibit a greater risk for severe immune-related adverse effects, patients with preexisting autoimmune disease receiving immune checkpoint inhibitors for melanoma had better 2-year survival than controls, according to data.

Dermatopathologists were often influenced by prior diagnoses when giving second opinions, especially in challenging cases, according to a study.

Although the number of Americans insured through Medicaid has increased during the past decade, barriers to cancer care access exist among Medicaid beneficiaries across high-quality centers, according to study results in JAMA Network Open.